Therapeutic efficacy of glucan in a murine model of hepatic metastatic disease
David L. Williams, Edward R. Sherwood, Rose B. McNamee, Ernest L. Jones, Nicholas R. Di Luzio – 1 March 1985 – Glucan, a particulate β‐1,3‐polyglucose immunomodulator, was evaluated for its ability to modify hepatic metastases and survival in mice with reticulum cell sarcoma. Sarcoma M5076 cells were injected subcutaneously (1 × 105 cells) into syngeneic C57BL/6J male mice. On Day 20, histopathological studies indicated the presence of hepatic micrometastases. At this time, glucan (0.45 mg per mouse) or dextrose was administered intravenously.